<DOC>
	<DOCNO>NCT00215670</DOCNO>
	<brief_summary>The objective study characterize safety , tolerability pharmacokinetics pegaptanib give 1 3mg/eye intravitreous injection every 6 week 54 week patient subfoveal choroidal neovascularization ( CNV ) secondary AMD .</brief_summary>
	<brief_title>Study Safety , Tolerability Pharmacokinetics 1 Mg/Eye 3 Mg/Eye Pegaptanib Sodium Patients With Exudative Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Best correct visual acuity study eye 20/40 20/320 good equal 20/800 fellow eye . Subfoveal CNV , secondary AMD , w/ total lesion size [ include blood , scar/atrophy &amp; neovascularization ] less equal 12 disc area , least 50 % must active CNV . Patients either sex , age great equal 50 year . Previous subfoveal thermal laser therapy . Any subfoveal scarring atrophy &amp; 25 % total lesion size may make scar atrophy . More one prior PDT w/ Visudyne permit . Pts may rec 'd 1st PDT w/in le 8 wks 13 wks prior BSL angiography/photography study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>AMD</keyword>
	<keyword>Macugen</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>PK</keyword>
</DOC>